New onset pruritus following discontinuation of cetirizine or levocetirizine
Year: 2025
Type: article
Language: en
Topic: Dermatology and Skin Diseases
Authors and affiliations:
raw_author_name: Karen Konkel
raw_affiliation_strings: Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD. Electronic address: Karen.Konkel@fda.hhs.gov
Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Karen.Konkel@fda.hhs.gov
raw_author_name: Jenni Yoon Lee
raw_affiliation_strings: Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Jenni.Lee@fda.hhs.gov
raw_author_name: S. Christopher Jones
raw_affiliation_strings: Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Steven.Jones@fda.hhs.gov
raw_author_name: Modupeola Adereti
raw_affiliation_strings: Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Modupeola.Adereti@fda.hhs.gov
raw_author_name: Sheheryar Muhammad
raw_affiliation_strings: Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Sheheryar.Muhammad@fda.hhs.gov
raw_author_name: Ragha Suresh
raw_affiliation_strings: Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Ragha.Suresh@fda.hhs.gov
raw_author_name: Rekha Jhamnani
raw_affiliation_strings: Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Rekha.Jhamnani@fda.hhs.gov
raw_author_name: Jody Green
raw_affiliation_strings: Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Nonprescription Drugs I, Office of Nonprescription Drugs, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: greenmax5505@gmail.com
raw_author_name: Rajdeep Gill
raw_affiliation_strings: Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Rajdeep.Gill@fda.hhs.gov
raw_author_name: Lynda McCulley
raw_affiliation_strings: Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD
Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20903, United States. Electronic address: Lynda.Mcculley@fda.hhs.gov